ClinicalTrials.gg
CompletedNCT03255993Updated Nov 15, 2021

The Tolerability and Pharmacokinetics of Multiple Doses of SPH3127 in Chinese Healthy People

A Phase 1 interventional study of SPH3127 50mg and SPH3127 100mg in Hypertension, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-15.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 410 studies in Hypertension with a site in China — 125 open to participants now, 148 under way, 12 of them phase 3. Hypertension · China.

Enrollment
284th of 308
24 · median 253
Started
2017
with 18 others
Phase 1
19 of 410
4 open now
Registered
133rd of 410
by date

Among the 410 studies in Hypertension with a site in China, this one is the 284th largest by enrollment of the 308 interventional ones that give a count, is one of 19 that started in 2017, is one of 19 in phase 1, and was the 133rd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.

Browse Hypertension studies →

Open to participants now

125 of the 410 studies in Hypertension with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 410 studies in Hypertension with a site in China, or all of them as a file.
02

Study summary

This study was a single center, parallel, randomized, double blind, placebo-controlled phase Ib clinical trial to to evaluate the safety and tolerability and pharmacokinetics of SPH3127 tablet in healthy subjects by increasing multiple dosing

Read the detailed description

Three panels(100mg, 200mg, 400mg), each consisting of eight participants (The number of individual subjects in each group was not less than 1/3 of the total number).Participants begin to receive the first dose of SPH3127 100mg. Then Participants begin to receive the second dose of SPH3127 200mg,after the researchers confirmed that the 100mg dose group was safe and well tolerated.Then the third dose of SPH3127 400mg must wait for the result of the second dose's safety and tolerability. If the subjects during escalating dose to the biggest tolerate dose group were not well tolerated, the study must adjust the maximum dose group and fall to a low dose group to conduct another test.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The is 18-28kg/m2 (including the critical value), which allows the minimum weight of men to be 50kg (including the critical value) and 45kg for women (including the critical value).
  2. Before the study,participant has know about the significance , potential benefits, inconveniences and potential risks of the study
  3. Participant has understood the research's procedure and sign the .

Exclusion criteria

Exclusion Criteria:

  • Participant who are Pregnancy, lactating women, and planned trials begin within six months of pregnancy
  • Participant who has abnormal Physical examination, laboratory examination results and clinical significance (such as: liver function examination - (AST) and alanine aminotransferase (ALT) more than 1.5 times that of the )
  • Participant who has a history of cardiovascular, liver, kidney, digestive tract, nervous system, blood system, familial hematologic disease, abnormal thyroid function, or mental abnormality
  • Participant who has drug allergy history and anaphylactic reaction
  • Participant who took oral in 6 months
  • Participant who used any drug (including Chinese herbal medicine) within 1 week.
  • Participant who donated blood within 2 months
  • Participant who participated clinical trials of any drug in 3 months (as subjects)
  • Participant who has any positive result of virus serology check: antigen antibody (HIV Ag/Ab) and virus (HCV) - immunoglobulin G(IgG) antibody to IgG, surface antigen (HBsAg) and treponema pallidum antibody (TP)
  • Participant who are used to smoke, alcohol abuse, eat coffee and strong tea and drug abuse
  • Participant who the researchers believe that there are volunteers who are not suitable for the study
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    SPH3127 100mg

    A single dose of SPH3127 50 mg\*2 qd \*7 days

    Drug: SPH3127 50mg

  • Placebo comparator
    Placebo to SPH3127 100mg

    A single dose of placebo matching to SPH3127 50mg\*2 qd \*7 days

    Drug: Placebo matching to SPH3127 50mg

  • Experimental
    SPH3127 200mg

    A single dose of SPH3127 100 mg\*2 qd \*7 days

    Drug: SPH3127 100mg

  • Placebo comparator
    Placebo to SPH3127 200mg

    A single dose of placebo matching to SPH3127 100mg\*2 qd \*7 days

    Drug: Placebo matching to SPH3127 100mg

  • Experimental
    SPH3127 400mg

    A single dose of SPH3127 100 mg\*4 qd \*7 days

    Drug: SPH3127 100mg

  • Placebo comparator
    Placebo to SPH3127 400mg

    A single dose of placebo matching to SPH3127 100mg\*4 qd \*7 days

    Drug: Placebo matching to SPH3127 100mg

Interventions

  • SPH3127 50mg

    Also known as: SPH3127 is a new study drug for hypertension

  • SPH3127 100mg

    Also known as: SPH3127 is a new study drug for hypertension

  • DrugPlacebo matching to SPH3127 50mg

    Placebo matching to SPH3127 50mg

    Also known as: Placebo is oral tablet to matching to SPH3127 50mg

  • DrugPlacebo matching to SPH3127 100mg

    Placebo matching to SPH3127 100mg

    Also known as: Placebo is oral tablet to matching to SPH3127 50mg

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs)

    to assess incidence and intensity of Adverse Events according to Common Toxicity Criteria (CTC version 4.03) associated with increasing doses of SPH3127

    Time frame: Baseline to 13-16 days post last dose

Secondary outcomes

  1. Plasma area under curve (AUC)(0-∞) of SPH3127

    to evaluate Plasma AUC(0-∞) of SPH3127

    Time frame: 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7; 10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6

  2. Change from baseline in laboratory hematology values

    to evaluate the Change from baseline in laboratory hematology values

    Time frame: Baseline to 13-16 days post last dose

  3. Change from baseline in laboratory chemistry values

    to evaluate the Change from baseline in laboratory chemistry values

    Time frame: Baseline to 13-16 days post last dose

  4. Change from baseline in laboratory urinalysis values

    to evaluate the Change from baseline in laboratory urinalysis values

    Time frame: Baseline to 13-16 days post last dose

  5. Change from baseline in ECG

    to evaluate the Change from baseline in ECG

    Time frame: Baseline to 13-16 days post last dose

  6. Maximum Plasma Concentration (Cmax) of SPH3127

    to evaluate Plasma Cmax of SPH3127

    Time frame: 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6

  7. Plasma Maximum time to peak (Tmax) of SPH3127

    to evaluate Plasma Tmax of SPH3127

    Time frame: 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6

  8. Apparent terminal half-life of SPH3127

    to evaluate terminal half-life of SPH3127

    Time frame: 10 minutes predose, 0.17hour, 0.33hour, 0.5hour, 0.75hour, 1hour, 1.25hour, 1.5hour, 2hour, 4hour, 6hour, 8hour, 12hour postdose at Day 1 and 7;10 minutes predose at Day 2; 10 minutes predose, 1hour postdose at Day 5 or 6

07

Study locations

1 site
  • The capital medical university affiliated Beijing anzhen hospital
    Beijing, Beijing 100029, China
08

References and documents

Publications

  • Jing S, Xu R, Yang K, Liu W, Zhang L, Ke Y, Xia G, Lin Y. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SPH3127: A Phase I, Randomized, Double-Blind, Placebo-Controlled Trial. Clin Ther. 2021 Apr;43(4):735.e1-735.e14. doi: 10.1016/j.clinthera.2021.01.025. Epub 2021 Feb 27. PubMed 33653620 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Sep 2018, 10 months.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 10 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2017
First posted
Aug 21, 2017
StartActual
Oct 23, 2017
Primary completionActual
Sep 20, 2018
CompletionActual
Sep 20, 2018
Last update
Nov 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03255993
Responsible party
Sponsor
First posted
Aug 21, 2017
Start date
Oct 23, 2017
Primary completion
Sep 20, 2018
Completion
Sep 20, 2018
Last update
Nov 15, 2021

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPH3127

Start the discussion